Jump to Main Content

About ASH

Guideline Oversight Subcommittee

Committee Roster

Matthew Cheung, MD, MSc  ('24)

Appointed Members
Gregory Abel, MD, MPH  ('26)
Rachel  S. Bercovitz, MD, MS  ('25)
Michael  T. Byrne, DO  ('24)
Benjamin Djulbegovic, MD  ('26)
James  N. George, MD  ('26)
Sandra Haberichter, PhD  ('24)
Ming Y  Y. Lim, MBBChir  ('26)
Richard Lottenberg, MD  ('26)
Ryan  J. Mattison, MD  ('26)
Menaka Pai, MD, MSc, BSc, FRCPC  ('25)
Suely  Meireles Rezende, MD, PhD  ('26)
Matthew  D. Seftel, MD, FRCP, FRCPC, MPH  ('24)
Deirdra Terrell, PhD  ('24)

Ex Officio Members
Catherine  M. Bollard, MD  ('26)  - Blood Advances Editor-in-Chief
Adam Cuker, MD  ('25)  - Chair, Committee on Quality

Staff Liaison
Rob Kunkle

Committee Mandate

The Guideline Oversight Subcommittee, a subcommittee of the Committee on Quality, oversees the development of ASH clinical practice guidelines.


The chair (and vice chair, if appointed) of the Guideline Oversight Subcommittee serve a one-year renewable term. If not already a member of the Committee on Quality, the chair of the subcommittee serves as a liaison to the Committee on Quality for a term congruent to service on the subcommittee.


Members of the Guideline Oversight Subcommittee are appointed to three-year staggered terms. They include individuals with experience serving on guideline panels, clinical expertise in diverse hematologic diseases, and/or expertise or interest in guideline development methods.


The Guideline Oversight Subcommittee structure includes the chair of the Committee on Quality as well as the Blood Advances Editor-in-Chief as ex officio, non-voting members.


Members of the Guideline Oversight Subcommittee are required to participate in one-hour Zoom meetings held monthly and an in-person meeting held once per year at ASH Headquarters.


New ASH guideline panels include one member of the Guideline Oversight Subcommittee in an ex officio role, with responsibilities that include explaining and implementing ASH policies and procedures for guideline development. The ex officio panelist may be voting or non-voting depending on clinical expertise and interest. Participation may lead to recognition as an author of the guideline report and other publications, if usual criteria for authorship are met.